Related Experiment Video
Updated: Jun 28, 2026

Methyl-binding DNA capture Sequencing for Patient Tissues
Published on: October 31, 2016
Methylation-associated silencing of SFRP1 in renal cell carcinoma
Yasuo Awakura1, Eijiro Nakamura, Noriyuki Ito
1Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Abstract:
Secreted frizzled-related protein 1 (SFRP1) is a candidate tumor suppressor gene located at 8p11.2 and antagonizes the Wnt signaling pathway. Epigenetic inactivation of SFRP1 by methylation of its promoter CpG island has recently been reported in several types of cancers. In the present study, we examined the expression and methylation status of SFRP1 in renal cell carcinoma (RCC). Three RCC cell lines were tested and none expressed the SFRP1 transcript. Bisulfite sequencing of the SFRP1 promoter and treatment of the RCC cell lines with 5-aza-2'-deoxycytidine and/or trichostatin A revealed the association between SFRP1 expression and promoter hypermethylation. Methylation-specific PCR detected hypermethylation in 26/57 (45.6%) conventional RCC cases and 2/8 (25%) papillary RCC cases. Quantitative real-time PCR showed >3-fold decrease of SFRP1 expression in 33/34 (97.1%) conventional RCC cases. Microsatellite analysis showed loss of heterozygosity at the SFRP1 locus (D8S1180) in only 3/28 (10.7%) conventional RCC cases. The present findings indicate that methylation-associated silencing of SFRP1 frequently occurs in RCC and plays a pivotal role in early carcinogenesis. However, previous immunohistochemical studies on beta-catenin have suggested that activation of the canonical Wnt pathway through beta-catenin stabilization is infrequent in RCC. Thus, further basic studies are required to elucidate how the loss of SFRP1 activity contributes to the Wnt and other signaling pathways in RCC.
Insights
Secreted frizzled-related protein 1 (SFRP1) silencing by promoter hypermethylation is frequent in renal cell carcinoma (RCC). This epigenetic inactivation of SFRP1, a tumor suppressor, likely plays a key role in kidney cancer development.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Secreted frizzled-related protein 1 (SFRP1) is a tumor suppressor gene that inhibits Wnt signaling.
- Epigenetic silencing of SFRP1 via promoter methylation is implicated in various cancers.
- The role of SFRP1 in renal cell carcinoma (RCC) remains to be fully elucidated.
Purpose of the Study:
- To investigate the expression and methylation status of SFRP1 in RCC.
- To determine the association between SFRP1 promoter methylation and its expression in RCC.
- To assess the frequency of SFRP1 alterations in RCC development.
Main Methods:
- Analysis of SFRP1 transcript expression in RCC cell lines.
- Bisulfite sequencing and methylation-specific PCR for SFRP1 promoter methylation analysis.
- Quantitative real-time PCR for SFRP1 expression levels.
- Microsatellite analysis for loss of heterozygosity at the SFRP1 locus.
Main Results:
- SFRP1 expression was undetectable in tested RCC cell lines.
- SFRP1 promoter hypermethylation was detected in 45.6% of conventional RCC and 25% of papillary RCC cases.
- A significant decrease in SFRP1 expression (>3-fold) was observed in 97.1% of conventional RCC cases.
- Loss of heterozygosity at the SFRP1 locus was infrequent (10.7% in conventional RCC).
Conclusions:
- Methylation-associated silencing of SFRP1 is a common event in RCC.
- SFRP1 inactivation likely contributes to kidney cancer initiation.
- Further research is needed to understand SFRP1's role in Wnt and other signaling pathways in RCC, especially given conflicting data on beta-catenin activation.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MicroRNAs
